Phase I study of CPI-613® in combination with Bendamustine for relapsed and refractory T cell lymphoma
TCA Cycle Inhibition by CPI-613® Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)
CPI-613® enhances FOLFIRINOX response rate in stage IV pancreatic cancer
The Mitochondrial Metabolism inhibitor CPI-613® in combination with mFOLFIRINOX for pancreatic cancer.
The Mitochondrial Metabolism Inhibitor CPI-613® in Combination with High Dose Ara-C (HDAC) and Mitoxantrone is Highly Active in High Risk Relapsed or Refractory AML.
The Mitochondrial Metabolism Inhibitor CPI-613® in Combination with High Dose Ara-C (HDAC) and Mitoxantrone is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML).
A phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613® in Combination with High Dose Ara-C and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
A Phase I Study of the First in Class Mitochondrial Metabolism Inhibitor CPI-613® in Patients with Advanced Hematologic Malignancies
Translational Assessment of the Efficacy of CPI-613® Against Pancreatic Cancer in Animal Models Vs. Patients With Stage IV Disease
Evaluation of the first-in-class antimitochondrial metabolism agent CPI-613® in hematologic malignancies
Lipoic acid analogs induces ROS, leading to potent mitochondrial enzyme inhibition, metabolic dysfunction and cell death in tumor cells
Regulation of Pancreatic, Gliosarcoma, and Non-Small Lung Cancer via CPI-613®, a Novel Selective Anticancer Therapeutic Agent
Altered Lipid and Mitochondrial Metabolism are viable Targets in Acute Leukemia
Poster: Potent anti-cancer agents, non-redox-active lipoate derivatives, have pervasive, catastrophic regulatory effects on cancer cell metabolism